Lysozyme.

Lysozyme hydrolyses the peptidoglycan bond that holds bacterial cell walls together, and colostrum supplies lactoferrin and immunoglobulins that bind iron and coat bacterial surfaces. Lactoferrin loosens the outer membrane so lysozyme can reach the peptidoglycan behind it, which is why the two occur together in milk.

Lysozyme acts on peptidoglycan, and gram-positive organisms including many lactobacilli present a thick peptidoglycan wall, so the enzyme is not selective about which gram-positive cell it reaches. Strain resistance varies widely, so the two are worth separating in time rather than assumed to cooperate in one capsule.

Lysozyme hydrolyses the peptidoglycan backbone of gram-positive cell walls while propolis flavonoids and aromatic acids disturb the membrane beneath it. The pairing is long-standing practice in throat and oral lozenges.

Monolaurin destabilises lipid membranes, which loosens the envelope that shields peptidoglycan from enzymatic attack. Lysozyme then reaches the glycosidic bonds it cleaves more readily.

Lysozyme is itself a protein, and bromelain is a broad-acting protease that hydrolyses peptide bonds without much substrate selectivity. Blending the two in one uncoated dose lowers the lysozyme activity that survives to the target site.

Papain is a cysteine protease that digests dietary and supplemental proteins alike, including lysozyme. Co-formulating them without separate coating reduces the delivered muramidase activity.

Pepsin works on proteins at gastric pH and will cut lysozyme along with the rest of the protein load. Lysozyme is unusually acid-stable on its own, so the loss here comes from the added protease rather than the pH.

Lactoferrin sequesters free iron and destabilises the outer membrane of gram-negative organisms, which exposes the peptidoglycan layer that lysozyme hydrolyses. The two proteins occur together in tears, saliva and milk, and formulators pair them for that reason. This is settled protein biochemistry rather than a clinical outcome, so the pairing describes a mechanism and not a measured benefit.

Lysozyme acts on the peptidoglycan of susceptible gram-positive cells, and lactobacilli are gram-positive, so a formulator has to regard the pair as potentially self-limiting rather than automatically additive. Animal feeding work reports shifts in gut microbial composition with dietary lysozyme, which is a microbiota measure and not a clinical outcome. The practical point is sequencing and separation in a product, not a claimed joint effect.

Bifidobacteria carry a peptidoglycan wall reinforced by exopolysaccharide, and susceptibility to lysozyme differs strain to strain. Pairing the two is common in gut blends, and the honest framing is that the interaction is strain dependent rather than uniformly helpful or harmful. No human trial of the combination is cited here.

Lysozyme cleaves a bacterial peptidoglycan bond that yeast cell walls do not contain, so this yeast is not a substrate for it. That makes the pair mechanically compatible in one product in a way that a lysozyme plus gram-positive bacterium pair is not. It is a compatibility statement, not a claim of added benefit.

Inulin feeds saccharolytic colonic bacteria while lysozyme acts on susceptible bacterial walls higher in the tract, so the two work through unrelated routes on the same ecosystem. Animal feeding studies of dietary lysozyme report microbiota and intestinal morphology changes, which are measures rather than outcomes. Any joint effect in people is not established.

Galactooligosaccharides are fermented by bifidobacteria and are not affected by lysozyme activity, so the two coexist without competing chemistry. Both appear in infant and gut-support formulations for that reason. The combination has no human trial cited here and is offered as a mechanism-level pairing.

Yeast 1,3/1,6 beta-glucan is a dectin-1 and complement receptor 3 ligand, an entirely different route from enzymatic wall hydrolysis. A human trial of yeast glucan in healthy adults names salivary lysozyme among the mucosal immune markers it tracked, which links the two as markers rather than as a tested combination. Read that as mechanism overlap, not as a joint outcome.

Zinc carnosine is used for its effects on mucosal integrity and turnover, while lysozyme is a secreted antimicrobial protein of the same mucosal surfaces. The two act by unrelated mechanisms and are commonly formulated together in gut-lining products. No combination trial is cited.

Lysozyme is strongly cationic at gut pH and galloyl-rich tannins are polyanionic, so the two form insoluble complexes on contact. That complexation removes enzyme activity from solution, which matters for any tannin-heavy botanical taken in the same dose. It is a formulation and timing issue, not a toxicity one.

Galloylated catechins bind basic proteins including lysozyme and can precipitate them from solution. Co-dosing a concentrated catechin extract with a lysozyme product is therefore expected to lower measurable enzyme activity. Separating the two by time is the practical response.

Activated charcoal adsorbs proteins and small molecules without selectivity, so a co-ingested enzyme is adsorbed along with everything else. Any charcoal dose taken with lysozyme reduces the amount that reaches the intestine in active form. Standard practice is to space charcoal away from everything else.

Bentonite is an anionic aluminosilicate with a high cation-exchange capacity, and lysozyme is a cationic protein, so the clay binds it readily. This is one of the classic protein-clay adsorption pairs in food science. Expect lost activity when the two are taken together.

Pancreatin supplies trypsin and chymotrypsin, which hydrolyse dietary protein, and lysozyme is a protein substrate like any other. Co-dosing a proteolytic blend with lysozyme shortens its intact half-life in the small intestine. The point is order of exposure rather than an adverse effect.

Betaine hydrochloride is taken to lower gastric pH, and low pH with active pepsin is the condition under which dietary proteins are unfolded and cleaved. Lysozyme is comparatively acid tolerant for an enzyme, so the loss is partial rather than total. Where intact intestinal delivery is the aim, an enteric presentation or separate timing addresses it.